Jinfo BlogAI and analytics in pharma and life sciences

Wednesday, 3rd January 2018 Sign in to MyJinfo or create an account be able to star items Click for printable version Subscribe via RSS to get updates as soon as Blog items are added Tweet about this item on Twitter Share on Facebook Share on LinkedIn

By Catherine Dhanjal

« Blog

Abstract

We look at how are pharma and life science companies using machine learning, artificial intelligence and data analytics - and which are the vendors to watch.

Item

Keeping up to date with new tools and vendors in the artificial intelligence (AI) and data analytics space can seem daunting; it's an ever-changing mix and it's hard to know which up-and-coming vendors are worth watching.

The pharmaceutical and life sciences industry is certainly one where these technologies can have a huge impact on R&D as well as on areas such as medical procedures and diagnosis. So we were keen to commission an article tackling this topic and looking at how some of the billions of pounds invested by pharmaceutical companies are now being devoted to projects involving AI.


Pharma in top sectors for AI use

Author Jeanette Eldridge has deep experience of research in the healthcare, pharmaceutical and life science sectors, supporting researchers in areas such as drug-hunting projects, patent and literature reviews, through experience at organisations including AstraZeneca and Knoll Pharmaceuticals. 

In "New developments for pharma in AI and data analytics", she highlights why "machine-learning partnerships and analytics applications in the pharmaceutical industry, as well as in the wider healthcare and life sciences sectors, present one of the fastest-growing areas in artificial intelligence".


Plethora of partnerships

Jeanette explains that it's not just the newer entrants making an impact. Established "big data" tools such as IBM Watson are evolving and developing new uses in AI and pharma.

Then there are newer market entrants such as BenevolentAI where insights from data scientists are fed back into the system to improve accuracy in areas such as novel entity recognition.

Finally, pharmaceutical companies are creating projects using in-house skills or in collaboration with external entities such as cancer research centres.

Jinfo Subscribers can log in now to read the full article, "New developments for pharma in AI and data analytics".

« Blog

About this item

Click to visit the Jinfo Blog Related Blog items:

Click to view all Jinfo Subscription articles Related Subscription Articles:

Click to view all Jinfo Subscription Reports Related Subscription Reports:

What's new at Jinfo?


What else is new?

Explore by category


Register for our twice-monthly newsletter and keep up to date with what's new from Jinfo:

Latest: Jinfo Newsletter No.506 08 Nov 2018

Privacy policy and terms of use
(Opens in a new window)

Benefit from our research

Subscription

Claire Laybats, Head of Commercial DevelopmentConnect your team with the practical tools, original research and expertise to build and support information strategy in your organisation.

A Jinfo Subscription gives access to all Content (articles, reports, webinars) and Community.

Subscription benefits


Consulting

Robin Neidorf, Head of ConsultingOur proven processes, resources and guidance will help your team make the shift from transaction centre to strategic asset.

Read case studies, and start the conversation.

Consulting benefits